Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyanamide is a small molecule drug primarily used as an alcohol-deterrent therapy for the management of chronic alcoholism. Its mechanism of action involves inhibition of aldehyde dehydrogenase 2 (ALDH2), an enzyme responsible for metabolizing acetaldehyde produced during alcohol metabolism. By inhibiting ALDH2, cyanamide causes accumulation of acetaldehyde when alcohol is consumed, leading to unpleasant symptoms such as nausea and flushing that deter further drinking. Cyanamide has been approved and marketed in several countries (including Canada, Europe, and Japan) for this indication. It is also used industrially in the synthesis of pharmaceuticals and agrochemicals[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyanamide.